Most Accessed Articles

Immunomodulatory Drugs (IMiDs) in Multiple Myeloma

, 2017; 17(9): 846-857.

Shahzad Raza, Rachael A. Safyan and Suzanne Lentzsch*


DOI: 10.2174/1568009617666170214104426


Multiple Myeloma and the Immune Microenvironment

, 2017; 17(9): 806-818.

Yawara Kawano, Aldo. M. Roccaro, Irene M. Ghobrial* and Jamil Azzi*


DOI: 10.2174/1568009617666170214102301


HR+, HER2– Advanced Breast Cancer and CDK4/6 Inhibitors: Mode of Action, Clinical Activity, and Safety Profiles

, 2017; 17(7): 637-649.

Sarah L. Sammons, Donna L. Topping and Kimberly L. Blackwell*


DOI: 10.2174/1568009617666170330120452


Potential Anti-cancer Drugs Commonly Used for Other Indications

, 2015; 15(1): 35-52.

Veronika Hanusova, Lenka Skalova, Vera Kralova and Petra Matouskova


DOI: 10.2174/1568009615666141229152812


Impact of IL-12 in Cancer

, 2017; 17(8): 682-697.

Xinjie Lu*


DOI: 10.2174/1568009617666170427102729


Multimodal HDAC Inhibitors with Improved Anticancer Activity

, 2018; 18(1): 39-56.

Rainer Schobert and Bernhard Biersack*


DOI: 10.2174/1568009617666170206102613


P-glycoprotein Inhibition as a Therapeutic Approach for Overcoming Multidrug Resistance in Cancer: Current Status and Future Perspectives

, 2013; 13(3): 326-346.

Ziyad Binkhathlan and Afsaneh Lavasanifar


DOI: 10.2174/15680096113139990076


Electrochemotherapy as First Line Cancer Treatment: Experiences from Veterinary Medicine in Developing Novel Protocols

, 2016; 16(1): 43-52.

E. P. Spugnini, T. Azzarito, S. Fais, M. Fanciulli and A. Baldi


DOI: 10.2174/156800961601151218155340


Targeting the Immune Niche within the Bone Marrow Microenvironment: The Rise of Immunotherapy in Multiple Myeloma

, 2017; 17(9): 782-805.

K. Podar* and D. Jager


DOI: 10.2174/1568009617666170214103834


Webmaster Contact: info@benthamscience.org
Copyright © 2018 Bentham Science